S&P 500   3,375.58 (+0.06%)
DOW   27,937.78 (+0.15%)
QQQ   271.97 (-0.19%)
AAPL   457.11 (-0.64%)
MSFT   208.37 (-0.16%)
FB   259.50 (-0.69%)
GOOGL   1,511.11 (-0.37%)
AMZN   3,146.26 (-0.47%)
NVDA   460.52 (+0.61%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.95 (-0.41%)
AMD   81.54 (-0.37%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
S&P 500   3,375.58 (+0.06%)
DOW   27,937.78 (+0.15%)
QQQ   271.97 (-0.19%)
AAPL   457.11 (-0.64%)
MSFT   208.37 (-0.16%)
FB   259.50 (-0.69%)
GOOGL   1,511.11 (-0.37%)
AMZN   3,146.26 (-0.47%)
NVDA   460.52 (+0.61%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.95 (-0.41%)
AMD   81.54 (-0.37%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
S&P 500   3,375.58 (+0.06%)
DOW   27,937.78 (+0.15%)
QQQ   271.97 (-0.19%)
AAPL   457.11 (-0.64%)
MSFT   208.37 (-0.16%)
FB   259.50 (-0.69%)
GOOGL   1,511.11 (-0.37%)
AMZN   3,146.26 (-0.47%)
NVDA   460.52 (+0.61%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.95 (-0.41%)
AMD   81.54 (-0.37%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
S&P 500   3,375.58 (+0.06%)
DOW   27,937.78 (+0.15%)
QQQ   271.97 (-0.19%)
AAPL   457.11 (-0.64%)
MSFT   208.37 (-0.16%)
FB   259.50 (-0.69%)
GOOGL   1,511.11 (-0.37%)
AMZN   3,146.26 (-0.47%)
NVDA   460.52 (+0.61%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.95 (-0.41%)
AMD   81.54 (-0.37%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
Log in

NASDAQ:IDXGInterpace Diagnostics Group Stock Price, Forecast & News

$5.87
-0.17 (-2.81 %)
(As of 08/14/2020 12:42 PM ET)
Add
Compare
Today's Range
$5.87
Now: $5.87
$6.12
50-Day Range
$4.41
MA: $5.64
$7.06
52-Week Range
$3.81
Now: $5.87
$11.00
Volume3,882 shs
Average Volume195,315 shs
Market Capitalization$23.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Read More
Interpace Diagnostics Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:IDXG
CUSIP69329V10
Phone855-776-6419

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.08 million
Book Value$3.41 per share

Profitability

Net Income$-26,730,000.00
Net Margins-110.80%

Miscellaneous

Employees176
Market Cap$23.70 million
Next Earnings DateN/A
OptionableNot Optionable
$5.87
-0.17 (-2.81 %)
(As of 08/14/2020 12:42 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Interpace Diagnostics Group (NASDAQ:IDXG) Frequently Asked Questions

How has Interpace Diagnostics Group's stock price been impacted by Coronavirus?

Interpace Diagnostics Group's stock was trading at $6.46 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IDXG stock has decreased by 9.1% and is now trading at $5.87.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Interpace Diagnostics Group?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Interpace Diagnostics Group
.

How were Interpace Diagnostics Group's earnings last quarter?

Interpace Diagnostics Group Inc (NASDAQ:IDXG) released its quarterly earnings results on Thursday, June, 25th. The business services provider reported ($2.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.24) by $1.08. The business services provider earned $9.20 million during the quarter, compared to analyst estimates of $8.95 million. Interpace Diagnostics Group had a negative net margin of 110.80% and a negative return on equity of 145.12%.
View Interpace Diagnostics Group's earnings history
.

What guidance has Interpace Diagnostics Group issued on next quarter's earnings?

Interpace Diagnostics Group updated its second quarter 2020 After-Hours earnings guidance on Thursday, June, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.6-6 million, compared to the consensus revenue estimate of $6.27 million.

What price target have analysts set for IDXG?

5 Wall Street analysts have issued 12-month target prices for Interpace Diagnostics Group's shares. Their forecasts range from $3.00 to $12.00. On average, they anticipate Interpace Diagnostics Group's stock price to reach $8.81 in the next year. This suggests a possible upside of 50.1% from the stock's current price.
View analysts' price targets for Interpace Diagnostics Group
.

Has Interpace Diagnostics Group been receiving favorable news coverage?

News stories about IDXG stock have trended somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Interpace Diagnostics Group earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned news stories about the business services provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
View the latest news about Interpace Diagnostics Group
.

Are investors shorting Interpace Diagnostics Group?

Interpace Diagnostics Group saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 137,700 shares, a decline of 90.8% from the December 31st total of 1,500,000 shares. Based on an average daily volume of 51,200 shares, the days-to-cover ratio is currently 2.7 days. Approximately 4.3% of the shares of the stock are short sold.
View Interpace Diagnostics Group's Short Interest
.

Who are some of Interpace Diagnostics Group's key competitors?

What other stocks do shareholders of Interpace Diagnostics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Diagnostics Group investors own include Histogenics (HSGX), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), AT&T (T) and AVEO Pharmaceuticals (AVEO).

Who are Interpace Diagnostics Group's key executives?

Interpace Diagnostics Group's management team includes the following people:
  • Mr. Jack E. Stover, CEO, Pres & Director (Age 67, Pay $621.68k)
  • Mr. Gregory Richard, Sr. VP & Chief Commercial Officer (Age 53, Pay $424.24k)
  • Mr. Fred S. Knechtel, CFO, Treasurer & Company Sec. (Age 59)
  • Mr. Glenn Gershon, Sr. VP of Operations
  • Mr. Thomas John Freeburg, Chief Accounting Officer (Age 52)

What is Interpace Diagnostics Group's stock symbol?

Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG."

Who are Interpace Diagnostics Group's major shareholders?

Interpace Diagnostics Group's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Penbrook Management LLC (2.07%), Essex Investment Management Co. LLC (1.01%) and Virtu Financial LLC (0.29%).
View institutional ownership trends for Interpace Diagnostics Group
.

Which institutional investors are selling Interpace Diagnostics Group stock?

IDXG stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC.
View insider buying and selling activity for Interpace Diagnostics Group
.

Which institutional investors are buying Interpace Diagnostics Group stock?

IDXG stock was bought by a variety of institutional investors in the last quarter, including Penbrook Management LLC, and Virtu Financial LLC.
View insider buying and selling activity for Interpace Diagnostics Group
.

How do I buy shares of Interpace Diagnostics Group?

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Interpace Diagnostics Group's stock price today?

One share of IDXG stock can currently be purchased for approximately $5.87.

How big of a company is Interpace Diagnostics Group?

Interpace Diagnostics Group has a market capitalization of $23.70 million and generates $24.08 million in revenue each year. The business services provider earns $-26,730,000.00 in net income (profit) each year or ($5.58) on an earnings per share basis. Interpace Diagnostics Group employs 176 workers across the globe.

What is Interpace Diagnostics Group's official website?

The official website for Interpace Diagnostics Group is www.interpace.com.

How can I contact Interpace Diagnostics Group?

Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.